LARRY HUBBS: Open Payments
NPI 1316032519 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,631 in 88 payments from 19 companies in 2025. Trend: 2023 $1,474 · 2024 $1,322 · 2025 $1,631
Food & beverage: $1,631
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $266 |
| PFIZER INC. | 19 | $208 |
| Gilead Sciences, Inc. | 8 | $152 |
| Lilly USA, LLC | 7 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $114 |
| GlaxoSmithKline, LLC. | 6 | $105 |
| ABBVIE INC. | 4 | $93 |
| Novo Nordisk Inc | 4 | $77 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $66 |
| Exact Sciences Corporation | 4 | $64 |
Products named: AIRSUPRA, CAPLYTA, TRELEGY ELLIPTA, NURTEC ODT, MOUNJARO, Kerendia, PAXLOVID, Heplisav-B.
Industry payments across KY — which companies pay providers there.
